

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

olicant:

Osamu HONMOU et al.

Title:

INTERNALLY ADMINISTERED THERAPEUTIC AGENTS FOR DISEASES IN CENTRAL AND PERIPHERAL NERVOUS SYSTEM

COMPRISING MESENCHYMAL CELLS AS AN ACTIVE

INGREDIENT

Appl. No.:

10/562,202

International

6/25/2004

Filing Date:

371(c) Date:

04/13/06

Examiner:

Scott Long

Art Unit:

1633

Conf. No.:

4131

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR § 1.56**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of document(s) known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR § 1.56. Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of the Form PTO/SB/08 be returned in accordance with MPEP § 609.

A copy of the non-patent document is being submitted to comply with the provisions of 37 CFR §§ 1.97 and 1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR § 1.56(b). Applicants do not waive any rights to take any action which would be

appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

The listed document is being submitted in compliance with 37 CFR §1.97(c), before Final Action or Notice of Allowance.

Document G1 was cited in an Office Action mailed March 8, 2010, in related application Serial No. 12/149,646.

STATEMENT

The undersigned hereby states in accordance with 37 CFR §1.97(e)(2) that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of the information disclosure statement.

It is believed no fee is due in association with the present submission. The Commissioner is hereby authorized to charge any additional fees which may be required regarding this submission under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 15 April 2010

FOLEY & LARDNER LLP Customer Number: 22428

Telephone: Facsimile:

(202) 295-4621 (202) 672-5399 Sunit Talapatra

Attorney for Applicant Registration No. 54,482